These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The marketplace can't give us the drug safety data we need. Avorn J MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636 [No Abstract] [Full Text] [Related]
6. Post-marketing experience with an opioid nasal spray for migraine: lessons for the future. Loder E Cephalalgia; 2006 Feb; 26(2):89-97. PubMed ID: 16426261 [TBL] [Abstract][Full Text] [Related]
7. Medical devices on trial, Part I. Wright D Med Device Technol; 2002 Dec; 13(10):35-8. PubMed ID: 12575529 [TBL] [Abstract][Full Text] [Related]
8. Controlling type I error rate for fast track drug development programmes. Shih WJ; Ouyang P; Quan H; Lin Y; Michiels B; Bijnens L Stat Med; 2003 Mar; 22(5):665-75. PubMed ID: 12587098 [TBL] [Abstract][Full Text] [Related]
9. Finding value in the U.S. Food and Drug Administration's Fast Track program. Reichert JM; Rochon SL; Zhang BD Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299 [TBL] [Abstract][Full Text] [Related]
10. Evaluating drug effects in the post-Vioxx world: there must be a better way. Avorn J Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873 [No Abstract] [Full Text] [Related]
11. Safety in numbers--monitoring risk in approved drugs. Okie S N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493 [No Abstract] [Full Text] [Related]
12. New clinical trials policy at FDA. Vastag B Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196 [No Abstract] [Full Text] [Related]
16. Pharmacometrics at FDA: evolution and impact on decisions. Powell JR; Gobburu JV Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553 [TBL] [Abstract][Full Text] [Related]
17. FDA guidance document on monitoring delayed adverse events a good first start. Williams DA Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514 [No Abstract] [Full Text] [Related]
18. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing. Browar S Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949 [TBL] [Abstract][Full Text] [Related]
19. Industry looks to buck bias in emerging 'adaptive' designs. Torres C Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301 [No Abstract] [Full Text] [Related]
20. [From molecule to medicine--drug development]. Bruhn C Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355 [No Abstract] [Full Text] [Related] [Next] [New Search]